Stephens Inc. AR Lowers Position in Axon Enterprise, Inc (NASDAQ:AXON)

Stephens Inc. AR reduced its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 12.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,023 shares of the biotechnology company's stock after selling 421 shares during the period. Stephens Inc. AR's holdings in Axon Enterprise were worth $1,590,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in AXON. Arizona State Retirement System boosted its holdings in Axon Enterprise by 0.5% in the first quarter. Arizona State Retirement System now owns 20,927 shares of the biotechnology company's stock valued at $11,007,000 after acquiring an additional 107 shares during the last quarter. Realta Investment Advisors boosted its holdings in Axon Enterprise by 27.6% in the first quarter. Realta Investment Advisors now owns 2,265 shares of the biotechnology company's stock valued at $1,191,000 after acquiring an additional 490 shares during the last quarter. Xponance Inc. boosted its holdings in Axon Enterprise by 2.9% in the first quarter. Xponance Inc. now owns 16,939 shares of the biotechnology company's stock valued at $8,909,000 after acquiring an additional 470 shares during the last quarter. Kesler Norman & Wride LLC bought a new stake in Axon Enterprise in the first quarter valued at approximately $275,000. Finally, Fidelis Capital Partners LLC boosted its holdings in Axon Enterprise by 15.9% in the first quarter. Fidelis Capital Partners LLC now owns 619 shares of the biotechnology company's stock valued at $326,000 after acquiring an additional 85 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on AXON shares. The Goldman Sachs Group upped their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an "overweight" rating in a report on Friday, July 11th. Barclays upped their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Bank of America increased their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. Finally, Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $734.62.

Insider Activity at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the transaction, the executive directly owned 19,447 shares of the company's stock, valued at $14,405,559.72. This represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 9,905 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the sale, the president directly owned 298,809 shares of the company's stock, valued at $220,530,006.27. The trade was a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 over the last three months. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Stock Up 0.4%

Shares of NASDAQ:AXON traded up $3.09 during trading on Thursday, reaching $745.86. 341,015 shares of the stock were exchanged, compared to its average volume of 585,114. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21. The stock has a fifty day moving average of $760.96 and a two-hundred day moving average of $643.52. The firm has a market cap of $58.07 billion, a price-to-earnings ratio of 455.69, a price-to-earnings-growth ratio of 85.50 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the firm earned $1.15 earnings per share. Axon Enterprise's revenue for the quarter was up 31.3% on a year-over-year basis. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.